Department of Oncology, Chinese PLA General Hospital, Fuxing Road 28, Beijing, China.
Lifehealthcare Clinical Laboratories, Hangzhou, China.
BMC Cancer. 2021 Feb 15;21(1):162. doi: 10.1186/s12885-021-07829-1.
Urothelial carcinoma (UC) is the most common genitourinary malignancy in China. In this study, we surveyed the genomic features in Chinese UC patients and investigated the concordance of genetic alterations between circulating tumor DNA (ctDNA) in plasma and matched tumor tissue.
A total of 112 UC patients were enrolled, of which 31 were upper tract UC (UTUC) and 81 were UC of bladder (UCB). Genomic alterations in 92 selected genes were analyzed by targeted next-generation sequencing.
In the study cohort, 94.64, 86.61 and 62.50% of patients were identified as having valid somatic, oncogenic and actionable somatic alterations, respectively. The most frequently altered genes included TP53, KMT2D, KDM6A, FAT4, FAT1, CREBBP and ARID1A. The higher prevalence of HRAS (22.0% vs 3.7%) and KMT2D (59.26% vs 34.57%) was identified in UTUC than in UCB. Comparisons of somatic alterations of UCB and UTUC between the study cohort and western cohorts revealed significant differences in mutant prevalence. Notably, 28.57, 17.86 and 47.32% of the cases harbored alterations in FGFRs, ERBBs and DNA damage repair genes, respectively. Furthermore, 75% of the patients carried non-benign germline variants, but only two (1.79%) were pathogenic. The overall concordance for genomic alterations in ctDNA and matched tumor tissue was 42.97% (0-100%). Notably, 47.25% of alterations detected in ctDNA were not detected in the matched tissue, and 54.14% of which were oncogenic mutations.
We found a unique genomic feature of Chinese UC patients. A reasonably good concordance of genomic features between ctDNA and tissue samples were identified.
尿路上皮癌(UC)是中国最常见的泌尿生殖系统恶性肿瘤。在本研究中,我们调查了中国 UC 患者的基因组特征,并研究了血浆循环肿瘤 DNA(ctDNA)与匹配肿瘤组织之间遗传改变的一致性。
共纳入 112 例 UC 患者,其中 31 例为上尿路尿路上皮癌(UTUC),81 例为膀胱尿路上皮癌(UCB)。通过靶向下一代测序分析 92 个选定基因的基因组改变。
在研究队列中,分别有 94.64%、86.61%和 62.50%的患者被确定具有有效的体细胞、致癌和可操作的体细胞改变。最常改变的基因包括 TP53、KMT2D、KDM6A、FAT4、FAT1、CREBBP 和 ARID1A。与 UCB 相比,UTUC 中 HRAS(22.0%比 3.7%)和 KMT2D(59.26%比 34.57%)的发生率更高。与西方队列相比,研究队列中 UCB 和 UTUC 的体细胞改变比较显示突变流行率存在显著差异。值得注意的是,28.57%、17.86%和 47.32%的病例分别存在 FGFRs、ERBBs 和 DNA 损伤修复基因的改变。此外,75%的患者携带非良性种系变异,但只有 2 例(1.79%)为致病性变异。ctDNA 和匹配肿瘤组织中基因组改变的总体一致性为 42.97%(0-100%)。值得注意的是,在 ctDNA 中检测到的改变中有 47.25%未在匹配组织中检测到,其中 54.14%为致癌突变。
我们发现了中国 UC 患者独特的基因组特征。ctDNA 和组织样本之间的基因组特征具有较好的一致性。